It has been reported that affinity optimization of CD38 CAR could reduce “on‐target, off‐tumor” effects when targeting MM.[29] Despite the success of CD38 CAR targeting MM, AML, and B‐ALL, the application of CD38 CAR‐T cells in the treatment of T‐ALL is scarce. Here, CD38 is linked to Miyoshi myopathy.